RT Book, Section
A1 Maciocia, Paul M.
A1 Maciocia, Nicola C.
A1 Pule, Martin A.
A2 Kaushansky, Kenneth
A2 Prchal, Josef T.
A2 Burns, Linda J.
A2 Lichtman, Marshall A.
A2 Levi, Marcel
A2 Linch, David C.
SR Print(0)
ID 1178737809
T1 Immune Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy
T2 Williams Hematology, 10e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260464122
LK accessmedicine.mhmedical.com/content.aspx?aid=1178737809
RD 2022/05/27
AB SUMMARYAdoptive  cellular  therapy,  in  which  immune  cells  are  selected  or  engineered  to  direct  specificity  toward  diseased  cells,  has  recently  proved  efficacious  in  some  cancers,  particularly  including  several  of  the  hematologic  malignancies.  These  therapies  include  tumor-infiltrating  lymphocytes,  T-cell  receptor  transgenic  cells,  and  chimeric  antigen  receptor  (CAR)  T  cells,  with  the  latter  being  the  most  advanced  for  the  treatment  of  hematologic  malignancies.  To  produce  CAR  T  cells,  T  lymphocytes  are  engineered  to  express  synthetic  immune  signaling  molecules,  which  fuse  the  specificity  of  an  anti-tumor  monoclonal  antibody  with  the  potent  cytotoxic  and  immunosurveillance  functions  of  T  cells.  In  clinical  studies,  CAR  T  cells  have  engendered  deep  and  long-lasting  remissions  in  children  and  young  adults  with  resistant  and  relapsed  acute  lymphoblastic  leukemia  and  in  adults  with  diffuse  large  B-cell  lymphoma,  with  further  promising  data  in  myeloma.  Although  CAR  T-cell  therapy  has  the  potential  to  transform  cancer  treatment  as  part  of  the  “personalized  medicine”  revolution,  important  obstacles  remain  to  be  overcome.  These  include  identification  of  further  tumor-specific  targets,  enhancement  of  efficacy  while  reducing  toxicity  and  cost,  and  increasing  patient  access.